1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Anti-Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2014-2024

Report Details

Cancer treatments – here’s your guide to R&D and sales potentials
Do you want to assess the future of cancer-treating medicines? Visiongain’s new report gives you revenue predictions for that industry from 2014, helping you stay ahead. You find financial data, R&D trends, opportunities and outlooks for therapy.

In that analysis you see forecasted sales to 2024 at overall world market, submarket, product and national level. You also assess emerging trends, technologies, and expected therapies.

Events shaping that pharmaceuticals industry – why cancer remains healthcare’s top priority
Discover, then, what the future holds for anti-cancer products. And find how patients can benefit. Read on to explore that industry and see what its future market could be worth.

Forecasts to 2024 and other analyses show you sales prospects

Besides revenue forecasting to 2024, you find historical data, growth rates and market shares. You assess quantitative and qualitative analyses, business news, outlooks and developments (R&D). You also gain 128 tables, 145 charts and four interviews.

Is finding data for cancer treatment a challenge? Finding information there just got easier. Our work lets you investigate the most promising and lucrative parts of applied oncology. Avoid missing out. Instead you can stay ahead in knowledge and benefit your influence.

Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses and decisions for medicines including biological drugs (biologics).

And the following sections show how you gain from our new investigation.

Outlooks for that world market and its submarkets – where does the money lie?
Along with prediction of overall world market value to 2024, our report shows you individual revenue forecasting of four submarkets at world level:
- Immunotherapy
- Chemotherapies
- Targeted treatments
- Hormone-based agents.

Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your company to develop. Assess leading brands too.

Forecasts for 25 leading drugs and 23 emerging therapies – see potentials
How will leading drugs perform to 2024 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:
- Avastin
- Herceptin
- Rituxan/MabThera
- Glivec/Gleevec
- Revlimid
- Alimta
- Velcade.

You also discover individual selling potentials of 23 rising and emerging therapies, including these:
- Beleodaq
- Zykadia
- Cyramza
- Imbruvica
- Gazyva.

There you discover how high sales can go, to 2024, finding drugs and years with highest predicted growth and revenues. You see what’s happening, then, understanding trends, competition, challenges and opportunities.

In our study you also find geographical revenue predictions.

Leading national markets – where lie highest revenues and growth?
Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharma companies will occur from 2014. See where and how.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
- United States (US)
- Japan
- Germany, France, United Kingdom (UK), Italy and Spain (the EU5 group)
- Brazil, Russia, India and China (BRIC nations).

There you find potential. Our analyses show sales growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2014 to 2024 will change medical prescribing and the commercial landscape. See what’s possible for R&D.

Research and deve

Table Of Contents

Anti-Cancer Drugs Industry and Market: Therapies, RandD and Forecasts 2014-2024
1. Report Overview
1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Cancer Treatments
2.1 The Physiology of Cancer - Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer - Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival - Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World - More Must Be Done
2.3 Treating Tumours - How Can We Fight Back?
2.3.1 Chemotherapy - The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy - A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents

3. The World Anti-Cancer Drug Market, 2014-2024
3.1 Global Anti-Cancer Drugs Market Forecast, 2014-2024
3.2 The Domination of Immunotherapies in 2013
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2014-2024 - The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2014-2024
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2014-2024 - A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2014-2024

4. Leading National Markets, 2014-2024
4.1 Anti-Cancer Drugs - Leading Markets, 2013
4.2 The US Anti-Cancer Drugs Market, 2014-2024 - Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2013
4.2.2 The US Anti-Cancer Drugs Market Forecast - A Matured Approach
4.2.3 The Regulatory Effect on the US Market
4.3 The Japanese Anti-Cancer Drug Market, 2014-2024 - Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2014-2024 - Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2014-2024 - Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2014-2024 - Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2014-2024 - Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2014-2024 - Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2014-2024 - Can it Fulfil its Potential?

5. The Top 25 Anti-Cancer Drugs, 2014-2024
5.1 Avastin (Roche) - The World Market Leader
5.1.1 Avastin Revenue, 2010-2013 - Mixed Growth
5.1.2 Avastin Revenue Forecast - Still No.1?
5.2 Herceptin (Roche) - The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2010-2013 - Still Rising
5.2.2 Herceptin Revenue Forecast - Generic Erosion
5.3 Rituxan/MabThera (Roche) - Slowing Growth
5.3.1 Rituxan Revenue, 2010-2013 - Still Strong
5.3.2 Rituxan Revenue Forecast - Heading for a Decline
5.4 Gleevec/Glivec (Novartis) - The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2010-2013
5.4.2 Glivec Revenue Forecast - What Does the Future Hold?
5.5 Revlimid (Celgene) - Celgene's Top Revenue Generator
5.5.1 Revlimid Revenue, 2010-2013 - Still on the Rise
5.5.2 Revlimid Revenue Forecast - A Long Term Leader?
5.6 Alimta (Eli Lilly) - A Slow Decline?
5.6.1 Alimta Revenue, 2010-2013
5.6.2 Alimta Revenue Forecast- Revenue Erosion Looming
5.7 Velcade (JandJ/Takeda) - Rising Steadily
5.7.1 Velcade Revenue, 2010-2013
5.7.2 Velcade Revenue Forecast - A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/ Merck KGaA) - Facing Tough Competition
5.8.1 Erbitux Revenue, 2010-2013
5.8.2 Erbitux Revenue Forecast - No More Growth?
5.9 Gardasil (Merck and Co) - The Rise of Preventions
5.9.1 Gardasil Revenue, 2010-2013
5.9.2 Gardasil Revenue Forecast - Still Growing Strong
5.10 Zytiga (Johnson and Johnson)
5.10.1 Zytiga Revenue, 2010-2013 - The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) - Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2010-2013 - The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast - A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2010-2013 - No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) - A Targeted Approach
5.13.1 Afinitor Revenue, 2010-2013 - Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2010-2013
5.14.2 Sprycel Revenue Forecast - How Long Will the Growth Last?
5.15 Tasigna (Novartis) - Moving on Up
5.15.1 Tasigna Revenue, 2010-2013
5.15.2 Tasigna Revenue Forecast - A Multi-Billion Dollar Product?
5.16 Sutent (Pfizer)
5.16.1 Sutent Revenue, 2010-2013
5.16.2 Sutent Revenue Forecast - No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2010-2013 - The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast - A Promising Start to the Decade
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2010-2013 - The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2010-2013
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) - Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2013
5.20.2 Yervoy Revenue Forecast - Will it Keep Growing?
5.21 Vidaza (Celgene) - What Growth Potential?
5.21.1 Vidaza Revenue, 2010-2013
5.21.2 Vidaza Revenue Forecast - Generic Impact
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2010-2013
5.22.2 Treanda Revenue Forecast - Stalled Growth?
5.23 Temodar/Temodal (Merck and Co.) - Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2010-2013
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) - The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2010-2013
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) - Beginning the Climb
5.25.1 Abraxane Revenue, 2012-2013
5.25.2 Abraxane Revenue Forecast

6. Drugs Approved in 2013-2014: Potential Future Blockbusters
6.1 Approved Treatments in 2014
6.1.1 Beleodaq (Topotarget/Spectrum Pharmaceuticals)
6.1.1.1 Market Potential
6.1.2 Zykadia (Novartis) - The Rise of Kinase Inhibitors
6.1.2.1 Market Potential
6.1.3 Cyramza (Eli Lilly) - A Breakthrough for Gastric Cancer?
6.1.3.1 Market Potential
6.2 Approved Treatments in 2013
6.2.1 Imbruvica (Pharmacyclics)
6.2.1.1 Market Potential
6.2.2 Gazyva (Roche) - The First Breakthrough Therapy
6.2.2.1 Market Potential
6.2.3 Gilotrif (Boehringer Ingelheim)
6.2.3.1 Market Potential
6.2.4 Mekinist (GSK) - A First-in-Class Treatment for Melanoma
6.2.4.1 Market Potential
6.2.5 Tafinlar (GSK) - A Partner for Mekinist
6.2.5.1 Market Potential
6.2.6 Kadycla (Roche) - A Future Star
6.2.6.1 Market Potential - A Replacement for Herceptin?
6.2.7 Pomalyst (Celgene)
6.2.7.1 Market Potential
6.3 Drugs Approved in 2012 - How They're Doing Now
6.3.1 Afinitor (Novartis) - Already a Blockbuster
6.3.1.1 Market Potential
6.3.2 Bosulif (Pfizer) - How Will it Perform?
6.3.2.1 Market Potential
6.3.3 Cometriq (Exelixis)
6.3.3.1 Market Potential
6.3.4 Erivedge (Roche) - Will It Become a Blockbuster?
6.3.4.1 Market Potential
6.3.5 Iclusig (Ariad)
6.3.5.1 Market Potential - Wider Uses?
6.3.6 Inlyta (Pfizer) - A Good Second-Line Option?
6.3.6.1 Market Potential
6.3.7 Kyprolis (Amgen)
6.3.7.1 Market Potential
6.3.8 Marqibo (Talon) - Will Its Revenue Grow?
6.3.8.1 Market Potential
6.3.9 Perjeta (Roche) - Joining the HER2 Family
6.3.9.1 Market Potential
6.3.10 Stivarga (Bayer)
6.3.10.1 Market Potential
6.3.11 Synribo (Teva)
6.3.11.1 Market Potential
6.3.12 Votrient (GSK)
6.3.12.1 Market Potential
6.3.13 Xtandi (Medivation) - Quickly Becoming a Popular Choice
6.3.13.1 Market Potential
6.3.14 Zaltrap (Sanofi)
6.3.14.1 Market Potential

7. Leading Companies for Cancer Treatments, 2014
7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche - Leader of the Pack
7.2.1 Oncology Pipeline - Investment in the Future
7.2.2 Roche's Future Direction in Cancer Treatment
7.3 Novartis - Closing the Gap on Roche
7.3.1 Oncology RandD Pipeline - What's the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene - Pressing Need to Diversify?
7.4.1Celgene's Oncology Pipeline - Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly - Reliant on Alimta
7.5.1 Oncology RandD Pipeline - What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca - Climbing up the Ladder
7.6.1 Oncology Pipeline - Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology RandD Pipeline - What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck and Co. - Prominent in Vaccines
7.8.1 Oncology Pipeline - Greater Focus on Cancer
7.8.2 The Future Direction of Merck

8. RandD Pipelines for Cancer Treatment
8.1 Breast Cancer Drugs Under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Palbociclib (Pfizer)
8.1.3 Veliparib (Abbvie)
8.1.4 NeuVax (Galena Biopharma)
8.1.5 Entinostat (Syndax)
8.2 Prostate Cancer Drugs Under Development
8.2.1 OMD-201 (Orion)
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs Under Development
8.3.1 Tecemotide (Merck Serono)
8.3.2 RG7446 (Roche)
8.3.3 Nivolumab (Bristol-Myers Squibb)
8.3.4 MEDI4736 (AstraZeneca)
8.3.5 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs Under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 TAS-102 (Taiho Pharmaceuticals)
8.4.4 HA-Irinotecan (Alchemia)
8.4.5 Aptocine (Light Sciences Oncology)
8.5 Cervical Cancer Drugs Under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck and Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs Under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs Under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec9 (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs Under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.8.4 SG2000 (Spirogen)
8.9 Bladder Cancer Drugs Under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin's Lymphoma Drugs Under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs Under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs Under Development
8.12.1 IMA901 (Immatics)
8.12.2 ASG-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs Under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck and Co.)

9. Qualitative Analysis of the Anti-Cancer Drug Market 2014-2024
9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment's Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment

10. Research Interviews
10.1 Interview with Mr Thomas Felzmann, CEO, Activartis Biotech GmbH, Vienna, Austria
10.1.1 Activartis Biotech and AV0113
10.2 Interview with Professor Philip Rudland, Chair of Biochemistry at the University of Liverpool
10.2.1 Identifying Markers in Cancer Cells
10.2.2 The Importance of Protein Expression
10.2.3. The Advancement of Diagnostics
10.2.4 The Future of the Anti-Cancer Drug Market
10.3 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University
10.3.1 On His Research Interests and their Utility in Anti-Cancer Drug Development
10.3.2 On the Evaluation of New Targets for Anti-Cancer Drugs
10.3.3 On Drug Resistance and Targeted Therapies
10.3.4 On the Future of Traditional Chemotherapy
10.3.5 On Future Developments in the Anti-Cancer Field
10.4 Interview with Dr Neil Butt, Director, Antitope Ltd.
10.4.1 On Immunogenicity in Therapeutic Proteins
10.4.2 On Antitope's Technologies to Assess and Reduce Immunogenicity
10.4.3 On an Alternative Way of Reducing Immunogenicity
10.4.4 On Biosimilars
10.4.5 On Future Developments in that Field

11. Conclusions of the Study
11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies - The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US - Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment - It's Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks

List of Tables
Table 1.1 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2013-2018
Table 1.2 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013
Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2013
Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2013
Table 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.2 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2012-2013
Table 3.3 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue Forecast ($bn), CAGR (%) and Market Share (%), 2013, 2018 and 2024
Table 3.4 Global Immunotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.5 Global Chemotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.6 Global Targeted Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.7 Global Hormone Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.1 Anti-Cancer Drugs Market Revenue ($bn) and Market Share (%) by Leading Country, 2013, 2018, 2024
Table 4.2 Leading National Anti-Cancer Drugs Markets: Revenue Forecast ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2014-2024
Table 4.3 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.4 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.5 EU5 Anti-Cancer Drugs Market Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.6 The BRIC Countries Anti-Cancer Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.7 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.8 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.9 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.10 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.1 Top 25 Anti-Cancer Drugs: Revenue ($bn) and Market Share (%), 2013
Table 5.2 Top 10 Anti-Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2013, 2018, 2024
Table 5.3 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024
Table 5.4 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024 (Contd.)
Table 5.5 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024 (Contd.)
Table 5.6 Avastin Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.7 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.8 Herceptin Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.9 Herceptin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.10 Rituxan/MabThera Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.11 Rituxan/MabThera Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.12 Glivec Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.13 Glivec Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.14 Revlimid Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.15 Revlimid Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.16 Alimta Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.17 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.18 Velcade Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.19 Velcade Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.20 Erbitux Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.21 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.22 Gardasil Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.23 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.24 Zytiga Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
Table 5.25 Zytiga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.26 Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.27 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.28 Tarceva Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.29 Tarceva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.30 Afinitor Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.31 Afinitor Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.32 Sprycel Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.33 Sprycel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.34 Tasigna Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.35 Tasigna Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.36 Sutent Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.37 Sutent: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.38 Nexavar Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.39 Nexavar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.40 Xgeva Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.41 Xgeva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.42 Zoladex Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.43 Zoladex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.44 Yervoy Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
Table 5.45 Yervoy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.46 Vidaza Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.47 Vidaza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.48 Treanda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
Table 5.49 Treanda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.50 Temodar Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.51 Temodar Revenue Forecast (%bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.52 Faslodex Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.53 Faslodex Revenue Forecast ($bn), Annual Growth (%) and CAGR, 2014-2024
Table 5.54 Abraxane Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.55 Abraxane: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.1 Beleodaq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.2 Zykadia: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.3 Cyramza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.4 Imbruvica: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.5 Gazyva: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.6 Gilotrif: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.7 Mekinist: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.8 Tafinlar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.9 Kadcyla: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.10 Pomalyst: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.11 Bosulif: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.12 Cometriq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.13 Erivedge: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.14 Iclusig: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.15 Inlyta: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.16 Kyprolis: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.17 Marqibo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.18 Perjeta: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.19 Stivarga: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.20 Synribo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.21 Votrient: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.22 Xtandi: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.23 Zaltrap: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 7.1 Anti-Cancer Drug Revenues ($bn) and Market Shares (%) of Leading Companies, 2012-2013
Table 7.2 Roche - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.3 Roche's Anti-Cancer Drug Development Pipeline, 2013
Table 7.4 Novartis - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.5 Novartis' Anti-Cancer Drug Pipeline, 2013
Table 7.6 Celgene - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.7 Celgene's Anti-Cancer Drug Pipeline, 2013
Table 7.8 Eli Lilly - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.9 Eli Lilly's Anti-Cancer Drug Pipeline, 2013
Table 7.10 AstraZeneca - Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
Table 7.11 AstraZeneca's Anti-Cancer Drug Pipeline, 2013
Table 7.12 Bristol-Myers Squibb - Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
Table 7.13 Bristol-Myers Squibb Anti-Cancer Drug Pipeline, 2013
Table 7.14 Merck - Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
Table 7.15 Merck's Anti-Cancer Drug Pipeline, 2013
Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012
Table 8.2 Breast Cancer Drugs under Development, 2013
Table 8.3 Prostate Cancer Drugs under Development, 2013
Table 8.4 Lung Cancer Drugs under Development, 2013
Table 8.5 Colorectal Cancer Drugs under Development, 2013
Table 8.6 Cervical Cancer Drugs under Development, 2013
Table 8.7 Stomach Cancer Drugs under Development, 2013
Table 8.8 Liver Cancer Drugs under Development, 2013
Table 8.9 Ovarian Cancer Drugs under Development, 2013
Table 8.10 Bladder Cancer Drugs under Development, 2013
Table 8.11 Non-Hodgkin's Lymphoma Drugs under Development, 2013
Table 8.12 Leukaemia Drugs under Development, 2013
Table 8.13 Kidney Cancer Drugs under Development, 2013
Table 8.14 Pancreatic Cancer Drugs under Development, 2013
Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2014
Table 9.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.